2325 Camino Vida Roble
Carlsbad, CA 92011
Imagine a future when getting a noninvasive, multi-disease diagnostic test at your annual medical exam is as common as having your temperature or blood pressure taken. Imagine tests that can detect early biomarkers of cancer, Alzheimer’s, diabetes, autism or heart disease long before symptoms present. Imagine that when disease is detected, doctors can prescribe a treatment plan designed specifically for you. This is the future of personalized medicine.
RiboMed Biotechnologies, Inc. is developing sensitive diagnostic tests for early disease detection, drug development and treatment monitoring. These tests will find “Needles in a Haystack”, detecting those few disease cells that are present at the earliest stages of disease or after treatment, when disease may recur. These tests will allow for noninvasive detection and monitoring from bodily fluids such as blood, saliva, urine or sputum.
RiboMed Biotechnologies, Inc. is a commercialization stage molecular diagnostic company focused on developing tests for the early and noninvasive detection and monitoring of cancer and other diseases.
Michelle Hanna, Ph.D., founded the Company in 1999 to commercialize the patented nucleic acid technologies developed in her academic laboratory during her tenure as a university professor. RiboMed has since developed and patented a novel molecular detection and signal amplification process, Abscription® whose promise has been recognized by receipt of $9 million in government grants and contracts as well as Frost and Sullivan’s Biological Detection Technologies Excellence in Research award in 2005. RiboMed worked with the Department of Defense (DARPA) and Department of Homeland Security (HSARPA) for seven years developing sensitive, specific and extremely rapid isothermal tests for the simultaneous detection of RNA viruses, DNA bacteria and protein toxins on a single device at a single temperature. Upon completion of these contracts in 2007, RiboMed returned to the original goal of the company, the detection of biomarkers associated with human disease.
· Founded by Dr. Michelle Hanna in 1999 to develop non-invasive, early cancer detection tests using nucleotide analogs developed while a biochemistry professor
· Invented Abscription®, a biomarker detection process
· Post 9/11: Approached by DOD (DARPA) to apply abscription to detection of biomarkers associated with bioterrorism agents
· Completed 6 contracts over 7 years with DARPA and the Dept. of Homeland Security. Developed detection tests for protein toxins (Ricin, BoTox, SEB), and pathogenic bacteria and viruses
· 2008 – Received funding from the National Cancer Institute to develop new methods to detect epigenetic gene silencing (DNA methylation) during the initiation of cancer and other disease.